Budesonide Suspension
Product Images NDC 0093-6817

10 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 0093-6817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Budesonide Structural Formula (Image 1)

Budesonide Structural Formula (Image 1)
Chemical structure diagram showing the molecular arrangement of Budesonide, including detailed bonding and functional groups relevant to its steroid framework.*
FDA Label Image

1 (Image 10)

1 (Image 10)
Packaging label for Budesonide Inhalation Suspension 1 mg/2 mL by Teva Pharmaceuticals USA, Inc. The label specifies 6 pouches each containing five 2 mL unit-dose ampules (30 ampules total). It notes the product is a sterile suspension for oral inhalation use only, not for injection, and is used with a jet nebulizer, not an ultrasonic nebulizer. Manufactured in England by Norton Healthcare Limited for Teva Pharmaceuticals USA.*
FDA Label Image

Figure 1: A 12 Week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 2)

Figure 1: A 12 Week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 2)
A line graph showing mean change from baseline in nighttime asthma symptoms over 12 weeks for Budesonide suspension dosed at 0.25 mg, 0.5 mg, and 1.0 mg once daily compared to placebo. The x-axis represents time intervals from baseline through Week 12, and the y-axis shows change in symptoms. All Budesonide doses reduce symptoms more than placebo, with statistical significance noted for each dose.*
FDA Label Image

Figure 2: A 12 Week Trial In Pediatric Patients Previously Maintained On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 3)

Figure 2: A 12 Week Trial In Pediatric Patients Previously Maintained On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 3)
A line graph depicting the mean change from baseline in nighttime asthma symptoms over 12 weeks for Budesonide suspension at doses of 0.25 mg twice daily and 0.5 mg twice daily compared to placebo. The graph shows symptom reduction trends across specified weekly intervals with significance p-values noted for both doses.*
FDA Label Image

Figure 3: A 12 Week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 4)

Figure 3: A 12 Week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 4)
A line graph showing mean change from baseline in nighttime asthma symptoms over 12 weeks for various doses of Budesonide suspension via respiratory inhalation, including placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily. The x-axis represents time intervals from baseline through week 12, and the y-axis represents mean symptom change.*
FDA Label Image

Figure 1 (Image 5)

Figure 1 (Image 5)
An instructional illustration showing hands holding a blister pack and peeling back foil to remove a tablet or capsule. The image is labeled as Figure 1 and depicts the process of opening a blister pack, commonly found in medication dispensing instructions.*
FDA Label Image

Figure 2 (Image 6)

Figure 2 (Image 6)
An instructional illustration showing a hand twisting the cap or top of a small inhalation device or vial, demonstrating how to open or activate the product for use. Labeled as Figure 2.*
FDA Label Image

Figure 3 (Image 7)

Figure 3 (Image 7)
An instructional illustration showing a hand holding a small inhalation suspension vial while another hand is using the thumb to twist and open its cap. The image demonstrates how to open a vial for inhalation suspension use.*
FDA Label Image

Figure 4 (Image 8)

Figure 4 (Image 8)
An instructional illustration showing a person preparing Budesonide 1 mg/2mL inhalation suspension. The image depicts a hand holding the bottle upright while the other hand is unscrewing the cap, demonstrating how to open the inhalation suspension vial prior to use.*
FDA Label Image

1 (Image 9)

1 (Image 9)
The image shows the unfolded carton label for Budesonide inhalation suspension by Teva Pharmaceuticals USA, Inc. It includes patient usage instructions with five illustrated steps on how to open and use the ampule with a nebulizer. Storage instructions specify temperature and handling precautions. The label notes the package contains 6 pouches of five 2 mL ampules (30 unit-dose ampules).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.